Why Abemaciclib for Metastatic Breast Cancer Patients?

Dear Dr. Renukaprasad A R, Metastatic Breast Cancer: Role of CDK 4/6 Inhibitor Cyclin-dependent kinase 4 and 6 (CDK 4/6) are proteins that fuel breast tumor proliferation, resulting in metastatic breast cancers (MBC). They are also responsible for the resistance to standard treatments. Abemaciclib, a CDK 4/6 inhibitor, helps arrest cell cycle progression, thus causing senescence and apoptosis. To learn more about the role of abemaciclib in MBC patients, be a part of an interactive session with the experts in oncology on the 21st of July 2022 at 07:00 PM IST. Session highlights: Abemaciclib - Different by design Responses in MBC patients Clinical case presentation on the role of abemaciclib Q&A with the experts - Tailoring treatment in HR+ HER2- MBC patients based on poor prognostic factors Ask the Speaker   India's Largest Online Community of Verified Doctors Pune - 411045, India info@docplexus.co.in�� |� +91 98500 36954 You are receiving this communication because you are registered member of Docplexus. Unsubscribe from this mailing list. *|LIST:DESCRIPTION|* *|LIST:ADDRESS|* *|REWARDS_TEXT|*